Eirini Panoilia

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

Eirini Panoilia, Emilie Schindler, Epaminontas Samantas et al. · Cancer Chemotherapy and Pharmacology · 2015 · 54 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10

From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part I–Extrapolation of a Covariate Model From Morphine to Zidovudine

EHJ Krekels, Michael Neely, Eirini Panoilia et al. · CPT Pharmacometrics & Systems Pharmacology · 2012 · 40 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

Apostolos Papachristos, Polychronis Kemos, Eirini Panoilia et al. · International Journal of Molecular Sciences · 2019 · 25 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept study

Jagtar Singh Nijjar, Katharine Abbott-Banner, Yolanda Alvarez et al. · Annals of the Rheumatic Diseases · 2024 · 12 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11